Candel Therapeutics CADL

Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off the shelf viral immunotherapies that elicit an individualized systemic anti tumor immune response to help patients fight cancer. The company engineers adenovirus and herpes simplex virus vectors to induce immunogenic cell death within the tumor microenvironment releasing tumor antigens and stimulating a proinflammatory environment that promotes both local and systemic anti tumor immunity. Its approach aims to convert immunologically cold tumors into hot tumors thereby enhancing responsiveness to other therapies such as radiotherapy and immune checkpoint inhibitors. Candel Therapeutics conducts its research and development activities primarily in the United States and retains worldwide development and commercialization rights for its programs.

As a clinical stage company Candel Therapeutics has not yet generated product revenue its financial resources have been derived from public offerings, private placements, and collaboration agreements. The company completed an initial public offering in July 2021 and has entered into agreements such as the RTW Purchase Agreement which provides potential milestone payments contingent on regulatory approval of its product candidates. Revenue to date consists of funding received under these collaborations and equity financings rather than sales of approved therapies.

The company operates through the following segments: Adenovirus based platform and Herpes Simplex Virus based platform.

• Adenovirus based platform: This segment focuses on aglatimagene an off the shelf adenovirus that expresses the herpes simplex virus thymidine kinase gene and is administered with the prodrug valacyclovir to induce tumor specific cell death and a systemic anti immune response. The platform is being evaluated in multiple solid tumor indications including localized prostate cancer, non small cell lung cancer, and pancreatic cancer with a phase 3 trial in prostate cancer having met its primary endpoint of disease free survival.
• Herpes Simplex Virus based platform: This segment centers on linoserpaturev a genetically modified herpes simplex virus designed to replicate selectively in nestin expressing tumor cells providing oncolytic activity combined with immunostimulatory properties. The platform is currently under investigation in recurrent high grade glioma with an ongoing investigator sponsored phase 1b trial and plans for further development in glioblastoma and other neurologic tumors.

Within the competitive landscape of immuno oncology Candel Therapeutics positions itself as a niche developer of viral immunotherapy competing with larger pharmaceutical and biotechnology firms such as Merck and Co, Bristol Myers Squibb, and Amgen that also pursue checkpoint inhibitors and cellular therapies. Its competitive advantages lie in the off the shelf nature of its viral vectors, the dual mechanism of direct tumor killing and immune stimulation, and the potential to convert cold tumors into hot tumors which may enhance the efficacy of existing therapies.

Candel Therapeutics serves patients with solid tumors and the healthcare providers that treat them including oncology centers, hospitals, and clinics that administer intratumoral injections. The company does not disclose specific customer names in its filing.